16.5: Institutional Oversight and Shared Responsibility

Cell Culture Textbook (Biot 77 IVC) · LibreTexts

0%

Contents

    Text

    Size
    100%
    Theme
    Typeface
    Line length
    Spacing

    Read aloud

    How

    Speed: 1×
    Light up
    Highlight

    Symbols: Mulberry Symbols, © 2018–2026 Steve Lee, CC BY-SA 4.0 (licence, the set), the site's own copies.

    From LibreTexts, under CC BY-NC-SA 4.0, as the source states it; its equations are written in TeX, which the PDF shows typeset. This page at LibreTexts.

    16.5: Institutional Oversight and Shared Responsibility

    An institutional review board, or IRB, reviews research involving human participants within the applicable framework. Its role includes evaluating protections for participants, consent, and the balance of risks and possible benefits. Researchers should work through the institution's process to determine whether and how a proposed activity falls within that review.

    An institutional biosafety committee, or IBC, reviews relevant research involving recombinant or synthetic nucleic acid molecules under the NIH Guidelines. It considers containment, facilities, practices, and personnel training. The timing and type of review depend on the research category and applicable institutional requirements.

    Specialized stem cell or embryo review addresses scientific and ethical issues that may require additional expertise. Animal research review addresses animal welfare when an activity involves research animals. These functions concern different questions. One committee's decision does not automatically answer every question within another committee's scope.

    Review function

    Main focus

    Relevant example

    Human research review

    Participant protections and consent

    New tissue collection for a study

    Biosafety review

    Containment practices and relevant nucleic acid research

    Proposed genetic modification

    Specialized stem cell review

    Sensitive developmental activities

    A proposed embryo model

    Regulatory product review

    Product development and intended clinical use

    An investigational cell product

    Oversight remains relevant after a project begins. A change in cell source, delivery method, genetic construct, or planned use may affect the original assessment. Report proposed changes through the applicable process before implementing changes that require review.

    Technicians support oversight by following approved procedures, documenting departures, and raising questions when records do not match the work. For example, a shipment described as a different cell type should prompt a source check before use. Continuing with an uncertain identity can compromise both the experiment and its approved scope.

    Responsibility is shared, but it is not vague. The investigator directs the study, the institution provides review systems, and staff maintain the records and practices within their roles. When the correct decision is unclear, preserve the material and evidence while seeking a documented determination.


    This page titled 16.5: Institutional Oversight and Shared Responsibility was last modified on Wed, 21 Oct 2026 01:35:45 GMT and is shared under a CC BY-NC-SA 4.0 license and was authored, remixed, and/or curated by Emalee MacKenzie.